Depressive Disorders in Epilepsy

Depression in Neurologic Disorders: Diagnosis and Management

Volumn , Issue , 2012, Pages 126-144

  Kanner, Andres M ^a,b,c  

^a RUSH MEDICAL COLLEGE   (United States)

^b Laboratory of EEG and Video EEG Telemetry   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anxiety disorder; Bidirectional relation; Interictal dysphoric disorder; Major depressive disorders

Indexed keywords

EID: 84879692128     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118348093.ch11     Document Type: Chapter

References (127)

1. Tellez-Zenteno JF, Patten SB, Jett é N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia, 48: 2336-2344, 2007.
2. American Psychiatric Association. Diagnostic and Statistical Manuel of Mental Disorders - Forth Edition. Washington, DC: American Psychiatric Press, 2000.
3. Forsgren L, Nystrom L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res, 6: 66-81, 1990.
4. Hesdorffer DC, Hauser WA, Annegers JF, et al. Major depression is a risk factor for seizures in older adults. Ann Neurol, 47: 246-249, 2000.
5. Hesdorffer DC, Hauser WA, Ludvigsson P, et al. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol, 59: 35-41, 2006.
6. Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms and treatment. Biol Psychiatry, 54: 388-398, 2003.
7. Kanner AM, Barry JJ, Gilliam F, et al. Anxiety disorders, sub-syndromic depressive episodes and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy? Epilepsia, 51: 1152-1158, 2010.
8. Wiegartz P, Seidenberg M, Woodard A, et al. Co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression. Neurology, 53, Suppl. 2: S3-S8, 1999.
9. Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav, 1 (2): 100-105, 2000.
10. Ettinger AB, Weisbrot DM, Nolan EE, et al. Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia, 39 (6): 595-599, 1998.
11. Hitiris N, Mohanraj R, Norrie J, et al. Predictors of pharmacoresistant epilepsy. Epilepsy Res, 75: 192-196, 2007.
12. Petrovski S, Szoeke CEI, Jones NC, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology, 75: 1015-1021, 2010.
13. Kanner AM, Byrne R, Chicharro A, et al. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology, 72: 793-799, 2009.
14. Anhoury S, Brown RJ, Krishnamoorthy ES, et al. Psychiatric outcome after temporal lobectomy: a predictive study. Epilepsia, 41: 1608-1615, 2000.
15. Christensen J, Vestergaard M, Mortensen P, et al. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol, 6: 693-698, 2007.
16. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry, 170: 205-228, 1997.
17. Jones JE, Hermann BP, Barry JJ, et al. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav, 4: S31-S38, 2003.
18. Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology, 62: 708-713, 2004.
19. Fukuchi T, Kanemoto K, Kato M, et al. Death in epilepsy with special attention to suicide cases. Epilepsy Res, 51: 233-236, 2002.
20. Bladin PF. Psychosocial diffi culties and outcome after temporal lobectomy. Epilepsia, 33 (5): 898-907, 1992.
21. Dr. Katz memo and briefi ng document to PCNS and PD advisory board. June 12, 2008. Briefi ng document for the July 10, 2008 Advisory Committee to discuss antiepileptic drugs (AEDs) and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefi ng/2008-4372b1-01-FDA-Katz.pdf.
22. Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: fi re or false alarm? Epilepsia, 50: 978-986, 2009.
23. Gibbons RD, Jur K, Brown CH, et al. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry, 66: 1354-1360, 2009.
24. Olesen JB, Hansen PR, Erdal J, et al. Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol Drug Saf, 19 (5): 518-524, 2010.
25. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA, 303: 1401-1409, 2010.
26. VanCott AC, Cramer JA, Copeland LA, et al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VS hospital system. BMC Med, 8: 4, 2010.
27. Hesdorffer DC, Berg AT, Kanner AM. An update on antiepileptic drugs and suicide: do we know any more now? Epilepsy Curr, 10 (6): 137-145, 2010.
28. Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics, 80: 909-917, 1987.
29. Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav, 11: 130-132, 2007.
30. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology, 61: 704-706, 2003.
31. Trimble RM, R ü Sch N, Betts T, et al. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure, 9: 249-254, 2000.
32. Nishikawa T, Scatton B. Evidence for a GABAeric inhibitory infl uence on serotonergic neurons originating from the dorsal raphe. Brain Res, 279: 325-329, 1983.
33. Lehrner J, Kalchmayr R, Serles W, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure, 8 (2): 88-92, 1999.
34. Perrine K, Hermann BP, Meador KJ, et al. The relationship of neuropsychological functioning to quality of life in epilepsy [see comments]. Arch Neurol, 52 (10): 997-1003, 1995.
35. Gilliam F, Kuzniecky R, Faught E, et al. Patient-validated content of epilepsy-specifi c quality-of-life measurement. Epilepsia, 38 (2): 233-236, 1997.
36. Cramer JA, Blum M, Reed M, et al. The infl uence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav, 4: 515-521, 2003.
37. Cramer JA, Blum D, Fanning K, et al. The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav, 5: 337-342, 2004.
38. Kanner AM. Depression and epilepsy: how can we explain their bidirectional relation? Epilepsia, 52, Suppl. 1: 21-27, 2011.
39. Mazarati AM, Siddarth P, Baldwin RA, et al. Depression after status epilepticus: behavioural and biochemical defi cits and effects of fl uoxetine. Brain, 131: 2071-2083, 2008.
40. Salzberg M, Kumar G, Supit L, et al. Early postnatal stress confers enduring vulnerability to limbic epileptogenesis. Epilepsia, 48 (11): 2079-2085, 2007.
41. Jones NC, Kumar G, O ' Brien TJ, et al. Anxiolytic effects of rapid amygdala kindling, and the infl uence of early life experience in rats. Behav Brain Res, 203 (1): 81-87, 2009.
42. Gilby KL, Sydserff S, Patey AM, et al. Postnatal epigenetic infl uences on seizure susceptibility in seizure-prone versus seizure-resistant rat strains. Behav Neurosci, 123 (2): 337-346, 2009.
43. Kanner AM. Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin North America, 27 (4): 865-880, 2009.
44. Kanner AM. Depression and epilepsy: do glucocorticoids and glutamate explain their relationship? Curr Neurol Neurosci Rep, 9 (4): 307-312, 2009.
45. Kanner AM. Mood disorder and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci, 10 (1): 39-45, 2008.
46. Kanner AM. Mood disorders in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol, 21 (2): 190-194, 2008.
47. Jobe PC. Affective disorder and epilepsy comorbidity in the genetically epilepsy-prone-rat (GEPR). In: Depression and Brain Dysfunction, eds. F Gilliam, AM Kanner and YI Sheline. London: Taylor & Francis, pp. 121-157, 2006.
48. Jobe PC, Mishra PK, Browning RA, et al. Noradrenergic abnormalities in the genetically epilepsy-prone rat. Brain Res Bull, 35: 493-504, 1994.
49. Meldrum BS, Anlezark GM, Adam HK, et al. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology (Berl), 76: 212-217, 1982.
50. Piette Y, Delaunois AL, De Shaepdryver AF, et al. Imipramine and electroshock threshold. Arch Int Pharmacodyn Ther, 144: 293-297, 1963.
51. Polc P, Schneeberger J, Haefely W. Effects of several centrally active drugs on the sleep wakefulness cycle of cats. Neuropharmacology, 18: 259-267, 1979.
52. Yanagita T, Wakasa Y, Kiyohara H. Drug-dependance potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav, 12: 155-161, 1980.
53. Robinson R, Drafts B, Fisher J. Fluoxetine increases GABAA receptor activity through a novel modulatory site. J Pharmcol Exp Ther, 304: 978-984, 2003.
54. Ye Z, Lu Y, Sun H, et al. Fluoxetine inhibition of glycine receptor activity in rat hippocampal neurons. Brain Res, 1239: 77-84, 2008.
55. Clinckers R, Smolders I, Meurs A, et al. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D2 and 5-HT1A receptors. J Neurochem, 89: 834-843, 2004.
56. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C] WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry, 57: 174-180, 2000.
57. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology, 60: 749-756, 2003.
58. Theodore WH, Giovacchini G, Bonwetsch R, et al. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia, 47 (3): 499-503, 2006.
59. Hasler G, Bonwetsch R, Giovacchini G, et al. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry, 62 (11): 1258-1264, 2007.
60. Favale E, Rubino V, Mainardi P, et al. The anticonvulsant effect of fl uoxetine in humans. Neurology, 45: 1926, 1995.
61. Favale E, Audenino D, Cocito L, et al. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure, 12: 316-318, 2003.
62. Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol, 27 (3): 133-136, 2004.
63. Alper KR, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry, 62: 345-354, 2007.
64. Bonanno G, Giambelli R, Raiteri L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci, 25: 3270-3279, 2005.
65. Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr, 10 (10): 808-819, 2005.
66. Zink M, Vollmayr B, Gebicke-Haerter PJ, et al. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology, 58(2): 465-473, 2010.
67. Zarate CA, Quiroz J, Payne J, et al. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull, 36: 35-83, 2002.
68. Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA., 102: 15653-15658, 2005.
69. McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology, 26: 368-375, 2002.
70. Capizzano AA, Jorge RE, Acion LC, et al. In vivo proton magnetic resonance spectroscopy in patients with mood disorders: a technically oriented review. J Magn Reson Imaging, 26 (6): 1378-1389, 2007.
71. Walter M, Henning A, Grimm S, et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry, 66 (5): 478-486, 2009.
72. Machado-Vieira R, Salvadore G, Ibrahim LA, et al. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des, 15 (14): 1595-1611, 2009.
73. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47: 351-354, 2000.
74. Zarate CA, Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 63 (8): 856-864, 2006.
75. Zarate CA, Jr, Quiroz JA, Singh JB, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry, 57: 430-432, 2005.
76. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole effi cacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry, 61: 822-825, 2007.
77. Heckers S, Stone D, Walsh J, et al. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry, 59: 521-529, 2002.
78. Mason GF, Sanacora G, Hundal R, et al. Preliminary evidence of reduced cortical GABA synthesis rate in major depression. Soc Neurosci, 2001. Abstr 142.6.
79. Sanacora G, Mason GF, Rothman DL, et al. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry, 159: 663-665, 2002.
80. Zobel A, Wellmer J, Schulze-Rauschenbach S, et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci, 254 (5): 303-311, 2004.
81. Mazarati AM, Shin D, Kwon YS, et al. Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis, 34 (3): 457-461, 2009.
82. Kumar G, Couper A, O ' Brien TJ, et al. The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology, 32 (7): 834-842, 2007.
83. López JF, Chalmers DT, Little KY, et al. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry, 43 (8): 547-573, 1998.
84. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry, 48 (8): 755-765, 2000.
85. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry, 57: 925-935, 2000.
86. Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci, 22 (8): 3251-3261, 2002.
87. Bowley MP, Drevets WC, Ongur D, et al. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry, 52: 404-412, 2002.
88. Ö ng ü r D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A, 95: 13290-13295, 1998.
89. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry, 45 (9): 1085-1098, 1999.
90. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull, 55: 585-595, 2001.
91. Cotter D, Mackay D, Landau S, et al. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry, 58: 545-553, 2001.
92. Cotter D, Mackay D, Chana G, et al. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex, 12: 386-394, 2002.
93. Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry, 157 (1): 115-118, 2000.
94. Bremner JD, Vythilingam M, Vermetten E, et al. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry, 51 (4): 273-279, 2002.
95. Coffey CE. The role of structural brain imaging in ECT. Psychopharmacol Bull, 30 (3): 477-483, 1994.
96. Sheline YI. Brain structural changes associated with depression. In: Depression and Brain Dysfunction, eds. F Gilliam, AM Kanner, YI Sheline. London: Taylor & Francis, pp. 85-104, 2006.
97. Crossin KL, Tai MH, Krushel LA, et al. Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Proc Natl Acad Sci U S A., 94: 2687-2692, 1997.
98. Lin JJ, Salamon N, Lee AD, et al. Reduced neocortical thickness and complexity mapped in mesial temporal lobe epilepsy with hippocampal sclerosis. Cereb Cortex, 17: 2007-2018, 2007.
99. Salgado PC, Yasuda CL, Cendes F. Neuroimaging changes in mesial temporal lobe epilepsy are magnifi ed in the presence of depression. Epilepsy Behav, 19: 422-427, 2010.
100. Bilevicius E, Yasuda CL, Silva MS, et al. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology, 75 (19): 1695-1701, 2010.
101. Mendez MF, Cummings J, Benson D, et al. Depression in epilepsy. Signifi cance and phenomenology. Arch Neurol, 43: 766-770, 1986.
102. Kraepelin E. Psychiatrie, Vol. 3. Leipzig, Germany: Johann Ambrosius Barth, 1923.
103. Bleuler E. Lehrbuch der Psychiatrie, 8th ed. Berlin, Germany: Springer, 1949.
104. Gastaut H, Morin G, Les è vre N. É tude du comportement des é pileptiques psychomoteurs dans l ' intervalle de leurs crises: les troubles de l ' activit é globale et de la sociabilit é. Ann Med Psychol (Paris), 113: 1-27, 1955.
105. Blumer D, Altshuler LL. Affective disorders. In: Epilepsy: A Comprehensive Textbook, Vol. II, eds. J Engel and TA Pedley. Philadelphia: Lippincott-Raven, pp. 2083-2099, 1998.
106. Mula M, Jauch R, Cavanna A, et al. Clinical and psychopathological defi nition of the interictal dysphoric disorder of epilepsy. Epilepsia, 49 (4): 650-656, 2008.
107. Blanchet P, Frommer GP. Mood change preceding epileptic seizures. J Nerv Ment Dis, 174: 471-476, 1986.
108. Williams D. The structure of emotions refl ected in epileptic experiences. Brain, 79: 29-67, 1956.
109. Weil A. Depressive reactions associated with temporal lobe uncinate seizures. J Nerv Ment Dis, 121: 505-510, 1955.
110. Daly D. Ictal affect. Am J Psych, 115: 97-108, 1958.
111. Gilliam FG, Barry JJ, Meador KJ, et al. Rapid detection of major depression in epilepsy: a multicenter study. Lancet Neurology, 5 (5): 399-405, 2006.
112. Jones JE, Herman BP, Woodard JL, et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia, 46 (5): 731-735, 2005.
113. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med, 146: 317-325, 2007.
114. Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav, 10 (1): 148-154, 2007.
115. Fakhoury TA, Barry JJ, Mitchell Miller J, et al. Lamotrigine in patients with epilepsy and comorbid depressive symptoms. Epilepsy Behav, 10 (1): 155-162, 2007.
116. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry, 160: 533-540, 2003.
117. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry, 40 (4): 163-168, 2007.
118. Gilliam FG, Black KJ, Carter J, et al. Depression and health outcomes in epilepsy: a randomized trial. Presented at the 61st Annual Meeting of the American Academy of Neurology, 25 April-02 May 2009, Seattle, Washington, USA, http://www.abstracts2view.com/aan2009seattle/view.php?nu=AAN09L_S26.002&terms.
119. Rosenstein D, Nelson J, Jacobs S. Seizures associated with antidepressants: a review. J Clin Psych, 54: 289-299, 1993.
120. Preskorn S, Fast G. Tricyclic antidepressant induced seizures and plasma drug concentration. J Clin Psych, 53: 160-162, 1992.
121. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry, 50: 256-261, 1989.
122. Trimble MR, Mula M. Antiepileptic drug interactions in patients requiring psychiatric drug treatment. In: Antiepileptic Drugs. Combination Therapy and Interactions, eds. J Majkowski, B Bourgeois, P Patsalos, R Mattson. Cambridge, UK: Cambridge University Press, pp. 350-368, 2005.
123. Patsalos P, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol, 2: 473-481, 2003.
124. Haney EM, Warden SJ, Bliziotes MM. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone, 46 (1): 13-17, 2010.
125. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med, 167 (12): 1240-1245, 2007.
126. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet, 351 (9112): 1303-1307, 1998.
127. Hirschfield RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry, 159, Suppl. #4: 1-15, 2002.